Table 1 Plasma concentration of lipids at baseline and 12 months after infliximab and etanercept therapy
Total (n = 65)Infl group (n = 44)Etan group (n = 21)
Baseline12 monthsBaseline12 monthsBaseline12 months
T Chol, mg/dl180 (35.2)197.7 (35.3)*181.9 (38.2)203.6 (36.6)§177.3 (27.2)184.8 (29.4)
HDL, mg/dl57.3 (20.1)59.8 (17.8)60.7 (22.9)60.7 (19.1)51.1 (12.7)58.2 (16.2)††
LDL, mg/dl104.8 (36.2)122.6 (32.8)†102.4 (35.7)128.5 (32.6)¶109.6 (39.4)110 (39.3)
TG, mg/dl101.6 (45.2)111.9 (64.7)110.1 (48.3)125.6 (70.9)84.1 (31.9)80.1 (31.7)
T Chol/HDL3.4 (1.0)3.5 (1.0)3.3 (1.1)3.6 (1.0)3.6 (1.1)3.5 (1.1)
LDL/HDL1.9 (0.9)2.2 (0.8)‡1.8 (0.86)2.3 (0.7)**2.1 (0.9)2.1 (1.1)
  • Baseline versus 12 months (Student t test): *p<0.0001; †p = 0.02; ‡p = 0.005; §p<0.001; ¶p = 0.003; **p = 0.01; ††p<0.05.

  • T Chol, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; Infl, infliximab; Etan, etanercept.